Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | ARG1 | P05089 | 2/20 | 0.35 |
| ▸ | ARG2 | P78540 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8510682 | 1.00 | NR1H2 (0.37) | NR1H2ARG1ARG2CHRM2CHRM1 | |
| SCHEMBL8510678 | 1.00 | NR1H2 (0.37) | NR1H2ARG1ARG2CHRM2CHRM1 | |
| SCHEMBL8510836 | 0.84 | PLG (0.42) | NR1H2ARG1ARG2PLGPLAT | |
| SCHEMBL8510838 | 0.84 | PLG (0.42) | NR1H2ARG1ARG2PLGPLAT | |
| SCHEMBL856162 | 0.84 | PLG (0.42) | NR1H2ARG1ARG2PLGPLAT | |
| SCHEMBL23523379 | 0.84 | PLG (0.42) | NR1H2ARG1ARG2PLGPLAT | |
| SCHEMBL23932191 | 0.84 | PLG (0.42) | NR1H2ARG1ARG2PLGPLAT | |
| SCHEMBL23932188 | 0.84 | PLG (0.42) | NR1H2ARG1ARG2PLGPLAT | |
| SCHEMBL2004619 | 0.84 | ARG1 (0.35) | ARG1ARG2CHRM2CHRM1CHRM3 | |
| SCHEMBL25348810 | 0.82 | NR1H2 (0.41) | NR1H2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865738-B2 | 5-membered heterocyclic compound cyclopenta[C]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2014-10-21 | — | — | US | disclosed |
| EP-2429998-B1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-11-27 | — | — | EP | disclosed |
| US-20120136026-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136026-A1 | 5-MEMBERED HETEROCYCLIC COMPOUND CYCLOPENTA[C]PYRROLYLALKYLCARBAMATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CA9, SCN9A, CCR9 | NR1H2 1782/4885ARG1 1032/4885ARG2 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.